Hosted by Unknown Host · EN-US · 48 episodes
Established thought leaders with verified media credentials.
Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy. Hosted by Marcus and Sara.
Unknown Host hosts Carl Haakon's Podcast, a general show with 48 episodes published.
Episode 47 — 06 July 2026 This episode covers PRAC valproate conclusions, HTA methodological updates in the Middle East, Canadian pricing policy developments, RWE integration challenges in Latin America, and gene therapy
Episode 46 — 05 July 2026 Analysis of recent JCA reports, NICE reversals, and transatlantic regulatory divergences with HEOR implications. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy a
Episode 45 — 04 July 2026 Deep dive into emerging JCA assessments, ADC portfolio implications, surrogate endpoint reversals, transatlantic regulatory crises, and pharmacovigilance precedents. Hosted by Marcus and Sara. A
Episode 44 — 03 July 2026 Examining gene therapy cost-effectiveness hurdles, RWE integration in HTA, PRO utility in value assessments, and evolving HTA approaches for digital health technologies. Hosted by Marcus and Sar
Episode 43 — 02 July 2026 Examining emerging market HTA thresholds, orphan drug RWE demands, digital therapeutics evidence gaps, geopolitical HTA challenges, and precision medicine HEOR shifts. Hosted by Marcus and Sara.
Episode 42 — 30 June 2026 Examining evolving HTA methodologies in emerging markets, pricing pressures in Canada, RWE adoption hurdles in Latin America, and gene therapy evidence strategies in Asia-Pacific. Hosted by Marc
Episode 41 — 29 June 2026 EMA CHMP approves eight treatments including rare disease; MHRA-NICE issues first aligned guidance; EU JCA scales up to 50 assessments with capacity challenges. Hosted by Marcus and Sara. Access
Episode 40 — 28 June 2026 JCA reports reveal HTA evolution, while ADC evidence gaps and regulatory divergence challenge commercial strategies. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strate
Episode 39 — 27 June 2026 Examining evolving HTA evidence demands, gene therapy value hurdles, and IRA-driven HEOR shifts. Contrarian perspectives on RWE adoption and evidence generation priorities. Hosted by Marcus and
Episode 38 — 26 June 2026 Examining FDA accelerated oncology approvals, EMA adaptive trial updates, NICE's new cell gene therapy framework, and emerging Asia-Pacific HTA collaboration. Hosted by Marcus and Sara. Access B
Episode 37 — 25 June 2026 Interim CDF recommendations for ADCs, NICE reversal on MRD endpoints, regulatory crises, JSC submissions, and EMA emergency trials. Hosted by Marcus and Sara. Access Brief — Daily briefings on H
Episode 36 — 25 June 2026 Examining regulatory divergence impacts on HEOR strategies and recent NICE reversals on MRD endpoints. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evi
Episode 35 — 22 June 2026 Examining PRAC valproate conclusions, EU JCA capacity expansion, EMA emergency trial frameworks, oral semaglutide UK access, and tovorafenib JCA procedural timelines. Hosted by Marcus and Sara.
Episode 25 — 08 June 2026 Medical device Joint Clinical Assessments begin in June 2026 as the EU HTA Regulation expands beyond oncology medicines. FDA approves first-in-class aldosterone synthase inhibitor baxdrostat whi
Episode 24 — 07 June 2026 NICE's revolutionary diabetes guideline makes SGLT-2 inhibitors first-line therapy while EU HTA regulation expands to high-risk medical devices. FDA accelerated approvals surge and EU clinical t
Episode 23 — 06 June 2026 Marcus and Sara examine the CHMP's May session showing 42% orphan designation rates and debate whether oral semaglutide represents genuine innovation or market expansion. They clash over emergen
Episode 22 — 05 June 2026 NICE approves third DMD treatment givinostat via Innovative Medicines Fund while CHMP's May output signals structural shift toward rare disease therapies. ISPOR 2026 highlights HEOR's expanding
Episode 21 — 04 June 2026 European Parliament and Council reach provisional agreement on Critical Medicines Act while EMA approves first RNA-based veterinary vaccine. ISPOR's latest trends report signals the shift from d
Episode 20 — 03 June 2026 Multiple first-in-class therapies create new HEOR value demonstration challenges while industry increasingly funds academic research to support policy positions. EMA's annual report reveals opti
Episode 19 — 02 June 2026 CHMP's May session approved eight medicines including oral semaglutide, signaling structural changes in European drug development. Medical device JCAs launch in June while AI tops ISPOR's 2026 t
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Carl Haakon's Podcast has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their general audience.
Carl Haakon's Podcast is hosted by Unknown Host. The show is categorised under General and has published 48 episodes.
Carl Haakon's Podcast has published 48 episodes.
Carl Haakon's Podcast is accessible for guests with genuine general expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Carl Haakon's Podcast hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Carl Haakon's Podcast average 5 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Carl Haakon's Podcast's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.